WHENMarch 23, 2013 @ 8:00am - 5:00pm
Date: Mar 23, 2013
Type: Association Events
Organizer: SABPA
Location: Institute of Americas, UCSD
Source: SABPA
SABPA Sci&Tech Forum 2013 Agenda 012413 WL.pdf
SABPA_Sci&Tech Forum 2013 Brochure.pdf

Innovations in Biologics Discovery and Development

Date: March 23, 2013, Saturday, 8:30am To 3:00pm (Lunch will be provided)

Location: Institute of Americas, UCSD

(Direction available at https://sabpa.org/web/IOA_UCSD-directions-map.pdf)

Registration: https://www.123signup.com/registerid=bmgsg

$20 for online registration, $10 for students and post-docs. $40 for on-site registration,

Online registration ends March 21, 2013


For the past two decades, biologics have revolutionized the treatment of diseases such as rheumatoid arthritis, psoriasis, Crohn’s disease, and multiple sclerosis, and are widely used in treating a variety of cancers. Biologics is a rapidly developing field of therapeutics and there is a trend for pharmaceutical and biotech industries to drift toward biologics development due to the promise of biologic drugs.


At the SABPA Science & Technology Forum XI, we bring together leaders in academic and pharma/biotech industry to discuss current trend in biologics discovery and development, as well as challenges facing the field. The presentations will address new technologies in discovering novel biologic therapeutics including the use of unnatural amino acids, somatic hypermutation and directed molecular evolution as well as developing biologics delivery platform. The meeting will cover therapeutic antibodies, proteins, peptides, vaccines and therapeutic areas from cancers, autoimmune to cardiovascular diseases.

Event Program

8:00-8:30 Registration & Breakfast
8:30-8:35 Opening Remarks
8:35-8:40 Chairperson of session 1
8:40-9:15 Peter Schultz, Ph.D.

Professor of Chemistry, Scripps Research Institute; and Director of California Institute for Biomedical Research

Title: A Chemists Foray into Translational Medicine.9:15-9:45Thomas F Bumol, Ph.D.

Vice President of Biotechnology and Autoimmunity, Lilly Research Laboratories, Lilly Biotechnology Center-San Diego

Title: Biotechnology as a Sustainable Source of Pharmaceutical Innovation: the Lilly Biotechnology Strategy.9:45-10:15David King, Ph.D.

Chief Scientific Officer, AnaptysBio Inc

Title: Generating Improved Antibody Therapeutics through Somatic Hypermutation in vitro10:15-10:40Refreshment Break, Exhibit & Networking10:40-10:45Chairperson of session 210:45-11:15Jeremy Barton, MD.

Vice President, Biotherapeutics Development, Pfizer

Title: Antibody Drug Conjugates: Blockbusters of the Next Decade

11:15-11:45Henry Ji, Ph.D.

Chief Executive Officer and President, Sorrento Therapeutics

Title: The G-MABLibrary Technology Discovery and Development of New Human Therapeutic Antibodies11:45-12:45Panel Discussion: Biologics Development


Steve Prestrelski, Ph.D., M.B.A.

Chief Scientific Officer, Xeris Pharmaceuticals, Inc.


1. Bhawanjit Brar, Ph.D., Senior Director, Zensun USA

2. Jean I Liu, M.S., J.D., Vice President, General Counsel and Secretary, Halozyme Therapeutics, Inc.

3. Brenden S. Gingrich, Ph.D., J.D., Partner, Knobbe Martens

4. Tim Tian, Ph.D., Senior Scientist, Laureate BioPharma

5. Olivier Laurent, Ph.D., Director, Protein Science, CovX12:45-12:50Closing Remarks:12:50-2:30Lunch


Link to Report:

Science tech forum report-2013